雷贝拉唑三联疗法治疗幽门螺杆菌相关十二指肠溃疡的临床疗效

曾贵利+李涛

[摘要] 目的 探讨雷贝拉唑三联疗法治疗幽门螺杆菌相关十二指肠溃疡的临床疗效。方法 方便选取2015年6—12月该院消化内科收治的幽门螺杆菌阳性的十二指肠溃疡患者80例作为观察对象。采用随机数表法将所有患者分为观察组与对照组，对照组40例患者采用常规奥美拉唑、阿莫西林、克拉霉素药物治疗，观察组40例患者则采用阿莫西林、克拉霉素联合雷贝拉唑治疗，比较两组患者药物治疗效果，并对比两组患者幽门螺杆菌根除率，随访复发率以及不良反应发生结果。 结果 观察组患者治疗后的总有效率为95.00%、幽门螺杆菌根除率为90.00%，明显高于对照组的77.50%、72.50%（P<0.05），但两组患者不良反应发生率比较差异无统计学意义（P>0.05）；并且随访1年结果显示观察组患者幽门螺杆菌相关十二指肠溃疡复发率（5.00%）明显低于对照组复发率（25.00%），差异有统计学意义（P<0.05）。 结论 采用雷贝拉唑三联疗法治疗幽门螺杆菌相关十二指肠溃疡临床疗效显著，并且患者幽门螺杆菌根除率较高，治疗后不易复发，可作为幽门螺杆菌阳性的十二指肠溃疡患者首选药物治疗方案。

[关键词] 雷贝拉唑三联疗法；幽门螺杆菌；十二指肠溃疡；临床疗效

[中图分类号] R4 [文献标识码] A [文章编号] 1674-0742（2017）03（b）-0147-03

[Abstract] Objective To study the clinical curative effect of triple therapy of rabeprazole in treatment of helicobacter pylori associated duodenal ulcers. Methods 80 cases of patients with helicobacter pylori associated duodenal ulcers admitted and treated in the digestive system department in our hospital from June to December 2015 were convenient selected and randomly divided into two groups with 40 cases in each， the control group adopted the routine treatment of omeprazole， amoxicillin and clarithromycin， while the observation group adopted the triple therapy of omeprazole， amoxicillin and clarithromycin， and the drug treatment effect was compared between the two groups， and the eradication rate of helicobacter pylori， recurrence rate of follow-up and adverse reactions were compared between the two groups. Results The total effective rate and eradication rate of helicobacter pylori after treatment in the observation group were obviously higher than those in the control group， （95.00%， 90.00% vs 77.50%， 72.50%），（P<0.05）， but the difference in the incidence rate of adverse reactions between the two groups had no statistical significance（P>0.05）， and the 1-year follow-up results showed that the recurrence rate in the observation group was obviously lower than that in the control group（5.00% vs 25.00%）， and the difference had statistical significance（P<0.05）. Conclusion The clinical curative effect of triple therapy of rabeprazole in treatment of helicobacter pylori associated duodenal ulcers is obvious with higher eradication rate of helicobacter pylori， and it is hard to recrudesce， which can be used as the primary drug treatment plan of positive patients with helicobacter pylori associated duodenal ulcers.

[Key words] Triple therapy of rabeprazole； Helicobacter pylori； Duodenal ulcers； Clinical curative effect

十二指腸溃疡是临床上最为常见的消化性溃疡之一，相关调查显示十二指肠溃疡发病率在所有消化性溃疡中仅次于胃溃疡，患者主要表现为周期性、节律性的上腹部疼痛、腹胀、恶心、反酸等，当治疗不及时或病情较重时可导致溃疡出血、穿孔等不良临床结局的发生[1]。现有临床研究结果证实，幽门螺杆菌感染是导致胃溃疡、十二指肠溃疡发生的重要原因之一，而临床治疗也以抑制胃酸分泌、抗幽门螺杆菌感染为主，目前质子泵抑制剂联合抗生素三联疗法治疗十二指肠溃疡是较为常用的手段，但药物应用方案相对较多，疗效以及药物应用的安全性方面也存在较大的差异[2-3]。为进一步提升幽门螺杆菌相关十二指肠溃疡的临床治疗效果，该组研究通过对2015年6—12月该院收治80例患者进行随机对照分析，探讨雷贝拉唑三联疗法治疗幽门螺杆菌相关十二指肠溃疡的临床疗效，现报道如下。